{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.65","upperLimit":"22.14","value":"10.84"},{"comment":"Insufficient number of events to calculate median value. Upper limit number not reached","groupId":"OG001","lowerLimit":"24.57","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"140"}],"units":"Participants"}],"description":"The time between the date of randomization and the date of first documented recurrence (local non-urothelial tract or distant), or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Placebo","id":"OG000","title":"Placebo"},{"description":"Nivolumab 240mg IV Q2W","id":"OG001","title":"Nivolumab"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants with PD-L1 expression ≥ 1%","reportingStatus":"POSTED","timeFrame":"up to 53 months","title":"Non-Urothelial Tract Recurrence Free Survival in PD-L1 Expression ≥ 1% Population","type":"SECONDARY","unitOfMeasure":"Months"}